|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of ATOH8 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 4:100,067,341...100,099,517
Ensembl chr 4:100,067,341...100,099,517
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid] |
CTD |
PMID:24709313 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of CYP1B1 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
increases expression |
ISO |
Pantothenic Acid results in increased expression of FAM43A mRNA |
CTD |
PMID:19397697 |
|
NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
|
|
G |
Fut7 |
fucosyltransferase 7 |
decreases expression |
ISO |
Pantothenic Acid results in decreased expression of FUT7 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 3:2,637,281...2,646,497
Ensembl chr 3:2,642,531...2,646,648
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of HMOX1 mRNA; Pantothenic Acid results in increased expression of HMOX1 protein |
CTD |
PMID:19397697 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspb7 |
heat shock protein family B (small) member 7 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of HSPB7 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 5:159,968,077...159,971,563
Ensembl chr 5:159,967,839...159,971,562
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Pantothenic Acid results in increased expression of ID1 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
increases expression |
ISO |
Pantothenic Acid results in increased expression of ID3 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 5:154,489,603...154,491,172
Ensembl chr 5:154,489,590...154,491,223
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Pantothenic Acid Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Pantothenic Acid] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of IL6 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Pantothenic Acid |
CTD |
PMID:20567778 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Marchf2 |
membrane associated ring-CH-type finger 2 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of MARCHF2 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 7:18,559,301...18,585,351
Ensembl chr 7:18,559,205...18,585,313
|
|
G |
Mtres1 |
mitochondrial transcription rescue factor 1 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of MTRES1 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr20:48,276,101...48,294,975
Ensembl chr20:48,275,762...48,294,948
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
multiple interactions |
ISO |
Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of MYB protein] |
CTD |
PMID:16112698 |
|
NCBI chr 1:16,658,178...16,690,135
Ensembl chr 1:16,659,442...16,687,817
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
Pantothenic Acid results in increased expression of MYCN mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 6:38,222,554...38,228,419
Ensembl chr 6:38,222,555...38,228,379
|
|
G |
Nhlrc1 |
NHL repeat containing E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of NHLRC1 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr17:18,059,382...18,060,572
Ensembl chr17:18,059,382...18,060,572
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nrep |
neuronal regeneration related protein |
increases expression |
ISO |
Pantothenic Acid results in increased expression of NREP mRNA |
CTD |
PMID:19397697 |
|
NCBI chr18:26,183,753...26,212,796
Ensembl chr18:26,185,259...26,211,445
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of PIM1 protein] |
CTD |
PMID:16112698 |
|
NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
|
|
G |
Pou3f4 |
POU class 3 homeobox 4 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of POU3F4 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr X:82,143,789...82,145,066
Ensembl chr X:82,143,789...82,145,066
|
|
G |
Ptprcap |
protein tyrosine phosphatase, receptor type, C-associated protein |
increases expression |
ISO |
Pantothenic Acid results in increased expression of PTPRCAP mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 1:219,403,970...219,406,129
Ensembl chr 1:219,403,970...219,406,128
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
increases expression |
ISO |
Pantothenic Acid results in increased expression of SLC51B mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
increases transport multiple interactions |
EXP ISO |
SLC5A6 results in increased transport of Pantothenic Acid Sodium affects the reaction [SLC5A6 results in increased transport of Pantothenic Acid] Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid] |
CTD |
PMID:9516450 PMID:10329687 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Pantothenic Acid results in decreased expression of SOX2 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
|
|
G |
Tmem18 |
transmembrane protein 18 |
increases expression |
ISO |
Pantothenic Acid results in increased expression of TMEM18 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 6:49,529,228...49,534,960
Ensembl chr 6:49,529,228...49,536,648
|
|
G |
Zfp575 |
zinc finger protein 575 |
decreases expression |
ISO |
Pantothenic Acid results in decreased expression of ZNF575 mRNA |
CTD |
PMID:19397697 |
|
NCBI chr 1:81,447,987...81,450,156
Ensembl chr 1:81,447,987...81,450,094
|
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
ISO |
Dabigatran results in decreased expression of AIF1 protein |
CTD |
PMID:27397090 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
Dabigatran results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
Dabigatran results in decreased expression of EYA1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
Dabigatran results in decreased activity of F2 protein |
CTD |
PMID:17911567 PMID:25138021 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions |
ISO |
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]] |
CTD |
PMID:25138021 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions |
ISO |
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]] |
CTD |
PMID:25138021 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
Dabigatran results in increased expression of FGF8 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Fgg |
fibrinogen gamma chain |
multiple interactions |
ISO |
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]] |
CTD |
PMID:25138021 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Foxc2 |
forkhead box C2 |
decreases expression |
ISO |
Dabigatran results in decreased expression of FOXC2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of GDNF mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Dabigatran results in decreased expression of GFAP protein |
CTD |
PMID:27397090 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
Dabigatran results in increased expression of HOXB9 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:84,119,772...84,124,963
Ensembl chr10:84,119,884...84,123,390
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
Dabigatran results in decreased expression of MEOX1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
increases expression |
ISO |
Dabigatran results in increased expression of MERTK mRNA |
CTD |
PMID:27397090 |
|
NCBI chr 3:121,235,230...121,340,932
Ensembl chr 3:121,235,119...121,342,444
|
|
G |
Neurog2 |
neurogenin 2 |
increases expression |
ISO |
Dabigatran results in increased expression of NEUROG2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 2:231,962,517...231,963,441
Ensembl chr 2:231,962,517...231,963,308
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of NR4A2 mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Olig3 |
oligodendrocyte transcription factor 3 |
increases expression |
ISO |
Dabigatran results in increased expression of OLIG3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:14,797,766...14,799,835
Ensembl chr 1:14,797,766...14,799,835
|
|
G |
Pax3 |
paired box 3 |
decreases expression |
ISO |
Dabigatran results in decreased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:84,004,004...84,101,226
Ensembl chr 9:84,005,183...84,101,172
|
|
G |
Pax6 |
paired box 6 |
increases expression |
ISO |
Dabigatran results in increased expression of PAX6 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
|
|
G |
Plp1 |
proteolipid protein 1 |
increases expression |
ISO |
Dabigatran results in increased expression of PLP1 mRNA |
CTD |
PMID:27397090 |
|
NCBI chr X:107,494,326...107,511,355
Ensembl chr X:107,496,072...107,511,348
|
|
G |
Rcor2 |
REST corepressor 2 |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RCOR2 mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 1:222,513,970...222,525,356
Ensembl chr 1:222,519,615...222,524,779
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RET protein] |
CTD |
PMID:28585189 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in increased expression of SNCA mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Tcf15 |
transcription factor 15 |
decreases expression |
ISO |
Dabigatran results in decreased expression of TCF15 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:147,643,250...147,649,511
Ensembl chr 3:147,643,250...147,649,504
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in decreased expression of TH mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Dabigatran inhibits the reaction [Rotenone results in increased expression of TNF mRNA] |
CTD |
PMID:28585189 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Uncx |
UNC homeobox |
decreases expression |
ISO |
Dabigatran results in decreased expression of UNCX mRNA |
CTD |
PMID:31711903 |
|
NCBI chr12:17,182,158...17,186,679
Ensembl chr12:17,182,163...17,186,679
|
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
ISO |
metalaxyl results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
metalaxyl results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
decreases expression |
ISO |
Methylphenidate results in decreased expression of AKR1B3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of AP2B1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:70,516,462...70,621,973
Ensembl chr10:70,520,206...70,621,977
|
|
G |
Arap1 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of ARAP1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:166,459,062...166,525,200
Ensembl chr 1:166,478,005...166,525,255
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
affects expression |
EXP |
Methylphenidate affects the expression of ARC mRNA |
CTD |
PMID:19222557 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Arih2 |
ariadne RBR E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of ARIH2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:117,387,004...117,446,085
Ensembl chr 8:117,387,010...117,446,019
|
|
G |
Armc9 |
armadillo repeat containing 9 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of ARMC9 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 9:93,172,718...93,299,119
Ensembl chr 9:93,172,673...93,296,750
|
|
G |
B4galt4 |
beta-1,4-galactosyltransferase 4 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of B4GALT4 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr11:64,558,006...64,584,054
Ensembl chr11:64,557,977...64,583,994
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
decreases expression |
ISO |
Methylphenidate results in decreased expression of BCL9 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:199,334,644...199,420,083
Ensembl chr 2:199,334,664...199,354,793
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects expression multiple interactions decreases expression |
EXP ISO |
Methylphenidate affects the expression of BDNF mRNA [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein] Methylphenidate results in decreased expression of BDNF mRNA |
CTD |
PMID:19222557 PMID:22470460 PMID:24394491 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
C2 |
complement C2 |
increases expression |
ISO |
Methylphenidate results in increased expression of C2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr20:4,542,340...4,561,152
Ensembl chr20:4,542,340...4,561,152
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of CALD1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Methylphenidate results in increased expression of CBR3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
|
|
G |
Ccdc166 |
coiled-coil domain containing 166 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CCDC166 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 7:117,039,890...117,041,693
Ensembl chr 7:117,039,892...117,041,693
|
|
G |
Ccdc91 |
coiled-coil domain containing 91 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CCDC91 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:181,873,465...182,043,593
Ensembl chr 4:181,874,861...182,043,593
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of CDK5R1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions increases hydrolysis increases metabolic processing |
ISO |
[CES1 protein results in increased hydrolysis of Methylphenidate] which results in increased chemical synthesis of ritalinic acid; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; CES1 gene mutant form results in decreased metabolism of and results in increased abundance of Methylphenidate; Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Thioridazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] CES1 protein results in increased metabolism of Methylphenidate |
CTD |
PMID:15082749 PMID:18485328 PMID:20097249 PMID:25445008 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Methylphenidate results in increased expression of CHD2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CHGA mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chid1 |
chitinase domain containing 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CHID1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:214,476,418...214,511,569
Ensembl chr 1:214,476,387...214,511,529
|
|
G |
Chrna6 |
cholinergic receptor nicotinic alpha 6 subunit |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CHRNA6 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr16:68,860,018...68,866,718
Ensembl chr16:68,860,018...68,866,718
|
|
G |
Chst8 |
carbohydrate sulfotransferase 8 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CHST8 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:90,542,095...90,685,257
Ensembl chr 1:90,542,096...90,685,257
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
increases expression |
ISO |
Methylphenidate results in increased expression of CLPX mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:70,789,137...70,843,133
Ensembl chr 8:70,789,256...70,843,123
|
|
G |
Cnnm1 |
cyclin and CBS domain divalent metal cation transport mediator 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of CNNM1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:263,184,361...263,243,912
Ensembl chr 1:263,186,235...263,242,468
|
|
G |
Cnot6l |
CCR4-NOT transcription complex, subunit 6-like |
decreases expression |
ISO |
Methylphenidate results in decreased expression of CNOT6L mRNA |
CTD |
PMID:22470460 |
|
NCBI chr14:15,059,101...15,148,255
Ensembl chr14:15,059,387...15,146,586
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of CNR1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Comtd1 |
catechol-O-methyltransferase domain containing 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of COMTD1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases expression |
EXP |
[Fluoxetine co-treated with Methylphenidate] results in increased expression of CREB mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of CREB protein Methylphenidate results in decreased expression of CREB mRNA |
CTD |
PMID:21753012 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
D2hgdh |
D-2-hydroxyglutarate dehydrogenase |
decreases expression |
ISO |
Methylphenidate results in decreased expression of D2HGDH mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 9:100,956,570...100,974,393
Ensembl chr 9:100,956,477...100,974,551
|
|
G |
Dab2 |
DAB adaptor protein 2 |
increases expression |
ISO |
Methylphenidate results in increased expression of DAB2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:55,747,353...55,768,848
Ensembl chr 2:55,747,318...55,768,270
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of DAPK3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Dhx35 |
DEAH-box helicase 35 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of DHX35 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 3:155,297,545...155,354,857
Ensembl chr 3:155,297,566...155,356,462
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methylphenidate |
CTD |
PMID:11454915 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions decreases expression affects expression |
EXP ISO |
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Methylphenidate Methylphenidate results in decreased expression of DRD2 mRNA Methylphenidate affects the expression of DRD2 protein |
CTD |
PMID:11454915 PMID:17599397 PMID:22470460 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Drd4 |
dopamine receptor D4 |
affects response to substance |
ISO |
DRD4 promoter mutant form affects the susceptibility to Methylphenidate |
CTD |
PMID:17023870 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
EXP |
[Fluoxetine co-treated with Methylphenidate] results in increased expression of EGR1 mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of EGR1 mRNA]; Methylphenidate promotes the reaction [Amphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of EGR1 mRNA] |
CTD |
PMID:16549270 PMID:19931852 PMID:20020108 PMID:21753012 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of ENTPD5 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:108,087,677...108,123,811
Ensembl chr 6:108,087,418...108,120,579
|
|
G |
Epb41l1 |
erythrocyte membrane protein band 4.1-like 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of EPB41L1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 3:152,492,725...152,622,047
Ensembl chr 3:152,552,822...152,619,722
|
|
G |
Epha10 |
EPH receptor A10 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of EPHA10 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:142,875,171...142,910,537
Ensembl chr 5:142,875,773...142,908,395
|
|
G |
Exog |
exo/endonuclease G |
decreases expression |
ISO |
Methylphenidate results in decreased expression of EXOG mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:128,133,398...128,153,110
Ensembl chr 8:128,133,431...128,153,110
|
|
G |
Fank1 |
fibronectin type III and ankyrin repeat domains 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of FANK1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371
|
|
G |
Fcgr2b |
Fc fragment of IgG receptor IIb |
increases expression |
ISO |
Methylphenidate results in increased expression of FCGR2B mRNA |
CTD |
PMID:22470460 |
|
NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of FOS mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of FOS mRNA] Methylphenidate results in increased expression of FOS protein Methylphenidate results in decreased expression of FOS protein SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA; Methylphenidate results in increased expression of FOS protein |
CTD |
PMID:12112414 PMID:12699766 PMID:15916815 PMID:19931852 PMID:21753012 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Methylphenidate results in increased expression of FOSB protein |
CTD |
PMID:15916815 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GALNT10 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:43,067,316...43,208,992
Ensembl chr10:43,067,299...43,210,427
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GCH1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GDNF mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Ghdc |
GH3 domain containing |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GHDC mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:88,672,834...88,677,055
Ensembl chr10:88,672,843...88,677,055
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GRIK3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546
|
|
G |
Gucy2c |
guanylate cyclase 2C |
decreases expression |
ISO |
Methylphenidate results in decreased expression of GUCY2C mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:170,659,993...170,740,274
Ensembl chr 4:170,659,998...170,740,274
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of HBP1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Homer1 |
homer scaffold protein 1 |
increases expression multiple interactions |
EXP |
Methylphenidate results in increased expression of HOMER1 mRNA SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of HOMER1 mRNA] |
CTD |
PMID:16549270 |
|
NCBI chr 2:22,909,550...23,012,303
Ensembl chr 2:22,909,569...23,009,678
|
|
G |
Hspb6 |
heat shock protein family B (small) member 6 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of HSPB6 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:89,008,117...89,010,256
Ensembl chr 1:89,008,117...89,010,256
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Methylphenidate results in increased expression of IL6 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ip6k1 |
inositol hexakisphosphate kinase 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of IP6K1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:116,781,957...116,826,152
Ensembl chr 8:116,804,451...116,823,540
|
|
G |
Jak3 |
Janus kinase 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of JAK3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
|
|
G |
Kifc3 |
kinesin family member C3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of KIFC3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:10,305,405...10,339,186
Ensembl chr19:10,320,604...10,339,178
|
|
G |
Lad1 |
ladinin 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LAD1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr13:52,645,257...52,659,619
Ensembl chr13:52,645,257...52,659,619
|
|
G |
Lama3 |
laminin subunit alpha 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LAMA3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr18:3,704,866...3,941,215
Ensembl chr18:3,705,916...3,940,838
|
|
G |
Large1 |
LARGE xylosyl- and glucuronyltransferase 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LARGE1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:12,481,563...12,945,320
Ensembl chr19:12,481,540...12,942,963
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of LASP1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:85,744,662...85,785,130
Ensembl chr10:85,744,568...85,785,133
|
|
G |
Lgals3bp |
galectin 3 binding protein |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LGALS3BP mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:107,415,334...107,424,672
Ensembl chr10:107,415,326...107,424,710
|
|
G |
Lhfpl5 |
LHFPL tetraspan subfamily member 5 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LHFPL5 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr20:5,815,837...5,826,137
Ensembl chr20:5,815,837...5,826,137
|
|
G |
Lrrc27 |
leucine rich repeat containing 27 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of LRRC27 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:211,543,751...211,575,823
Ensembl chr 1:211,543,751...211,575,820
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases expression |
ISO |
Methylphenidate results in decreased expression of MAP1LC3B mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases expression multiple interactions |
EXP |
Methylphenidate results in decreased expression of MAPK1 mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:21753012 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
Methylphenidate results in increased expression of MAPK8 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mlc1 |
modulator of VRAC current 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of MLC1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 7:129,949,984...129,970,314
Ensembl chr 7:129,949,967...129,970,550
|
|
G |
Morn2 |
MORN repeat containing 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of MORN2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:2,969,290...2,974,419
Ensembl chr 6:2,969,333...2,974,418
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions affects expression |
EXP |
[Fluoxetine co-treated with Methylphenidate] results in increased expression of MTOR mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MTOR protein Methylphenidate affects the expression of MTOR mRNA |
CTD |
PMID:21753012 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Mvp |
major vault protein |
decreases expression |
ISO |
Methylphenidate results in decreased expression of MVP mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:198,420,813...198,448,612
Ensembl chr 1:198,420,806...198,450,047
|
|
G |
Nabp1 |
nucleic acid binding protein 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of NABP1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 9:55,049,893...55,057,784
Ensembl chr 9:55,050,203...55,057,658
|
|
G |
Nacad |
NAC alpha domain containing |
decreases expression |
ISO |
Methylphenidate results in decreased expression of NACAD mRNA |
CTD |
PMID:22470460 |
|
NCBI chr14:86,860,607...86,868,605
Ensembl chr14:86,860,608...86,868,598
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of NCOR2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr12:36,871,917...37,033,701
Ensembl chr12:36,871,999...37,033,701
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
increases expression |
ISO |
Methylphenidate results in increased expression of NETO2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
|
|
G |
Nol3 |
nucleolar protein 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of NOL3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:37,232,567...37,236,668
Ensembl chr19:37,235,001...37,236,649
|
|
G |
Nsun4 |
NOP2/Sun RNA methyltransferase 4 |
increases expression |
ISO |
Methylphenidate results in increased expression of NSUN4 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:134,885,377...134,905,492
Ensembl chr 5:134,886,497...134,905,588
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]] |
CTD |
PMID:24394491 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Parp3 |
poly (ADP-ribose) polymerase family, member 3 |
increases expression |
ISO |
Methylphenidate results in increased expression of PARP3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:115,173,440...115,179,543
Ensembl chr 8:115,173,453...115,179,191
|
|
G |
Pear1 |
platelet endothelial aggregation receptor 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of PEAR1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:187,114,219...187,134,209
Ensembl chr 2:187,114,217...187,133,993
|
|
G |
Peds1 |
plasmanylethanolamine desaturase 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TMEM189 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 3:164,376,621...164,388,213
Ensembl chr 3:164,376,630...164,388,492
|
|
G |
Pisd |
phosphatidylserine decarboxylase |
decreases expression |
ISO |
Methylphenidate results in decreased expression of PISD mRNA |
CTD |
PMID:22470460 |
|
NCBI chr14:83,298,630...83,347,697
Ensembl chr14:83,298,674...83,346,738
|
|
G |
Pkn1 |
protein kinase N1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of PKN1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr19:24,803,524...24,832,305
Ensembl chr19:24,803,524...24,831,500
|
|
G |
Pnma8b |
PNMA family member 8B |
increases expression |
ISO |
Methylphenidate results in increased expression of PNMAL2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:78,876,205...78,878,779
Ensembl chr 1:78,876,205...78,878,779
|
|
G |
Prkg2 |
protein kinase cGMP-dependent 2 |
increases expression |
ISO |
Methylphenidate results in increased expression of PRKG2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr14:12,217,121...12,313,616
Ensembl chr14:12,218,553...12,315,229
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
ISO |
Methylphenidate results in decreased expression of PRLR mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:60,131,410...60,325,686
Ensembl chr 2:60,131,776...60,325,692
|
|
G |
Prpf39 |
pre-mRNA processing factor 39 |
increases expression |
ISO |
Methylphenidate results in increased expression of PRPF39 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:86,785,793...86,810,806
Ensembl chr 6:86,785,771...86,810,316
|
|
G |
Ptdss2 |
phosphatidylserine synthase 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of PTDSS2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:214,122,981...214,148,011
Ensembl chr 1:214,123,044...214,149,729
|
|
G |
Ptpn21 |
protein tyrosine phosphatase, non-receptor type 21 |
increases expression |
ISO |
Methylphenidate results in increased expression of PTPN21 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:122,656,500...122,721,496
Ensembl chr 6:122,656,500...122,721,496
|
|
G |
Pus7l |
pseudouridine synthase 7 like |
decreases expression |
ISO |
Methylphenidate results in decreased expression of PUS7L mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 7:135,765,307...135,803,818
Ensembl chr 7:135,765,303...135,800,481
|
|
G |
Rab38 |
RAB38, member RAS oncogene family |
increases expression |
ISO |
Methylphenidate results in increased expression of RAB38 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:152,072,716...152,153,449
Ensembl chr 1:152,072,665...152,153,449
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 7:141,277,303...141,308,849
Ensembl chr 7:141,277,312...141,307,233
|
|
G |
Rbfox1 |
RNA binding fox-1 homolog 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of RBFOX1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:8,312,961...10,437,778
Ensembl chr10:8,312,961...8,654,892
|
|
G |
Rcc2 |
regulator of chromosome condensation 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RCC2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:159,220,531...159,236,313
Ensembl chr 5:159,220,979...159,234,320
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RET mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Rgma |
repulsive guidance molecule BMP co-receptor a |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RGMA mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:134,699,053...134,742,512
Ensembl chr 1:134,699,299...134,742,514
|
|
G |
Rgs20 |
regulator of G-protein signaling 20 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RGS20 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:14,367,498...14,494,048
Ensembl chr 5:14,415,606...14,494,756
|
|
G |
Rhbdd2 |
rhomboid domain containing 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of RHBDD2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr12:24,091,132...24,102,081
Ensembl chr12:24,092,004...24,102,084
|
|
G |
Sdc3 |
syndecan 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SDC3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:148,923,098...148,956,404
Ensembl chr 5:148,923,098...148,956,404
|
|
G |
Siae |
sialic acid acetylesterase |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SIAE mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:40,078,269...40,113,514
Ensembl chr 8:40,078,269...40,113,514
|
|
G |
Slc10a4 |
solute carrier family 10, member 4 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SLC10A4 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr14:37,764,839...37,770,059
Ensembl chr14:37,764,839...37,770,059
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SLC18A2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases expression |
ISO |
Methylphenidate results in increased expression of SLC2A12 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:24,003,625...24,056,373
Ensembl chr 1:24,003,625...24,056,373
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions decreases expression increases response to substance affects response to substance |
ISO |
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] Methylphenidate results in decreased expression of SLC6A3 mRNA Methylphenidate results in decreased expression of SLC6A3 protein SLC6A3 protein results in increased susceptibility to Methylphenidate SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] SLC6A3 3' UTR polymorphism affects the susceptibility to Methylphenidate; SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate |
CTD |
PMID:12112414 PMID:12699766 PMID:15059031 PMID:16139732 PMID:17234900 PMID:18614672 PMID:19462300 PMID:22470460 PMID:31009648 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance |
ISO |
SNAP25 gene polymorphism affects the susceptibility to Methylphenidate |
CTD |
PMID:17023870 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Sncaip |
synuclein, alpha interacting protein |
increases expression |
ISO |
Methylphenidate results in increased expression of SNCAIP mRNA |
CTD |
PMID:22470460 |
|
NCBI chr18:47,739,284...47,877,679
Ensembl chr18:47,739,140...47,877,676
|
|
G |
Sncg |
synuclein, gamma |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SNCG mRNA |
CTD |
PMID:22470460 |
|
NCBI chr16:10,722,110...10,726,648
Ensembl chr16:10,722,106...10,726,707
|
|
G |
Snx22 |
sorting nexin 22 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SNX22 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:71,725,405...71,728,729
Ensembl chr 8:71,725,771...71,728,685
|
|
G |
Sorcs3 |
sortilin-related VPS10 domain containing receptor 3 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SORCS3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:267,986,305...268,620,331
Ensembl chr 1:268,189,277...268,620,331
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
increases expression |
ISO |
Methylphenidate results in increased expression of SOX11 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:46,629,967...46,631,988
Ensembl chr 6:46,629,974...46,631,983
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
decreases expression |
ISO |
Methylphenidate results in decreased expression of STAT5A mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
|
|
G |
Stox2 |
storkhead box 2 |
increases expression |
ISO |
Methylphenidate results in increased expression of STOX2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr16:47,994,555...48,233,588
Ensembl chr16:48,120,864...48,228,891
|
|
G |
Suds3 |
SDS3 homolog, SIN3A corepressor complex component |
decreases expression |
ISO |
Methylphenidate results in decreased expression of SUDS3 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr12:45,199,012...45,221,507
Ensembl chr12:45,199,577...45,221,512
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions |
ISO |
Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]] |
CTD |
PMID:17234900 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TH mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tmem185b |
transmembrane protein 185B |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TMEM185B mRNA |
CTD |
PMID:22470460 |
|
NCBI chr13:35,554,621...35,557,952
Ensembl chr13:35,554,964...35,556,016
|
|
G |
Tmem30a |
transmembrane protein 30A |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TMEM30A mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:87,222,107...87,245,953
Ensembl chr 8:87,223,948...87,245,951
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Methylphenidate results in increased expression of TNF mRNA |
CTD |
PMID:22470460 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Traf5 |
TNF receptor-associated factor 5 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TRAF5 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr13:110,758,556...110,801,871
Ensembl chr13:110,758,761...110,784,209
|
|
G |
Trim25 |
tripartite motif-containing 25 |
increases expression |
ISO |
Methylphenidate results in increased expression of TRIM25 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr10:76,343,847...76,362,159
Ensembl chr10:76,343,847...76,362,145
|
|
G |
Tspan17 |
tetraspanin 17 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TSPAN17 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr17:10,356,980...10,364,614
Ensembl chr17:10,356,936...10,364,570
|
|
G |
Ttf1 |
transcription termination factor 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of TTF1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 3:7,635,630...7,660,153
Ensembl chr 3:7,635,933...7,660,673
|
|
G |
Twsg1 |
twisted gastrulation BMP signaling modulator 1 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of TWSG1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 9:113,699,151...113,732,601
Ensembl chr 9:113,699,170...113,732,622
|
|
G |
Ube3d |
ubiquitin protein ligase E3D |
decreases expression |
ISO |
Methylphenidate results in decreased expression of UBE2CBP mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 8:93,948,689...94,120,477
Ensembl chr 8:93,948,767...94,120,458
|
|
G |
Ubxn10 |
UBX domain protein 10 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of UBXN10 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 5:157,158,129...157,165,767
Ensembl chr 5:157,159,936...157,165,767
|
|
G |
Uck2 |
uridine-cytidine kinase 2 |
decreases expression |
ISO |
Methylphenidate results in decreased expression of UCK2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr13:85,376,716...85,443,976
Ensembl chr13:85,376,716...85,443,976
|
|
G |
Vash1 |
vasohibin 1 |
increases expression |
ISO |
Methylphenidate results in increased expression of VASH1 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 6:110,624,377...110,640,942
Ensembl chr 6:110,624,856...110,637,382
|
|
G |
Wars2 |
tryptophanyl tRNA synthetase 2 (mitochondrial) |
decreases expression |
ISO |
Methylphenidate results in decreased expression of WARS2 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 2:201,170,363...201,256,115
Ensembl chr 2:201,172,312...201,255,703
|
|
G |
Zfp14 |
ZFP14 zinc finger protein |
decreases expression |
ISO |
Methylphenidate results in decreased expression of ZFP14 mRNA |
CTD |
PMID:22470460 |
|
NCBI chr 1:88,350,361...88,367,370
Ensembl chr 1:88,350,361...88,361,851
|
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
N-Methylaspartate results in increased phosphorylation of ELAVL1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in increased phosphorylation of ELAVL1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Go 6976 inhibits the reaction [N-Methylaspartate results in increased phosphorylation of ELAVL1 protein] |
CTD |
PMID:31945382 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases expression multiple interactions |
EXP |
N-Methylaspartate results in increased expression of MAPK1 protein modified form thieno(2,3-c)isoquinolin-5-one inhibits the reaction [N-Methylaspartate results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:22639866 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions |
EXP |
N-Methylaspartate results in increased expression of MAPK3 protein modified form thieno(2,3-c)isoquinolin-5-one inhibits the reaction [N-Methylaspartate results in increased expression of MAPK3 protein modified form] |
CTD |
PMID:22639866 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases ADP-ribosylation |
EXP |
N-Methylaspartate results in increased ADP-ribosylation of PARP1 protein |
CTD |
PMID:16903875 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Dizocilpine Maleate inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; Dizocilpine Maleate inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; ELAV1 protein mutant form inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; Go 6976 inhibits the reaction [N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein]; Go 6976 inhibits the reaction [N-Methylaspartate results in decreased expression of SIRT1 mRNA]; N-Methylaspartate results in decreased expression of and results in decreased activity of SIRT1 protein |
CTD |
PMID:31945382 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
affects binding |
ISO |
ABCC4 protein binds to nateglinide |
CTD |
PMID:17939016 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
ISO |
CYP2C9 protein affects the metabolism of Nateglinide |
CTD |
PMID:18159128 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Ins2 |
insulin 2 |
increases secretion |
ISO |
nateglinide results in increased secretion of INS protein |
CTD |
PMID:16403453 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity |
ISO |
Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein]; ferric chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein] |
CTD |
PMID:10086886 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
|
G |
Ahcy |
adenosylhomocysteinase |
increases hydrolysis |
ISO |
AHCY results in increased hydrolysis of S-Adenosylhomocysteine |
CTD |
PMID:26974671 |
|
NCBI chr 3:150,587,833...150,603,057
Ensembl chr 3:150,587,833...150,603,082
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases abundance multiple interactions |
ISO |
AHR protein results in increased abundance of S-Adenosylhomocysteine PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine] |
CTD |
PMID:29416063 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
multiple interactions |
ISO |
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
App |
amyloid beta precursor protein |
increases expression decreases methylation multiple interactions |
ISO |
S-Adenosylhomocysteine results in increased expression of APP protein S-Adenosylhomocysteine results in decreased methylation of APP promoter Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]; S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein |
CTD |
PMID:19635394 PMID:22064374 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases abundance |
ISO |
ATP7B protein mutant form results in increased abundance of S-Adenosylhomocysteine |
CTD |
PMID:22945834 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression |
ISO |
S-Adenosylhomocysteine results in increased expression of BACE1 protein |
CTD |
PMID:19635394 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
S-Adenosylhomocysteine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
S-Adenosylhomocysteine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases activity |
EXP |
S-Adenosylhomocysteine results in decreased activity of COMT protein |
CTD |
PMID:10064789 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases activity multiple interactions |
ISO |
S-Adenosylhomocysteine results in decreased activity of DNMT1 protein S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter] |
CTD |
PMID:16037419 PMID:22064374 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases abundance |
ISO |
FGF19 protein results in decreased abundance of S-Adenosylhomocysteine |
CTD |
PMID:29416063 |
|
NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions |
ISO |
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions |
ISO |
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression multiple interactions |
ISO EXP |
S-Adenosylhomocysteine results in increased expression of MMP2 mRNA; S-Adenosylhomocysteine results in increased expression of MMP2 protein S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter] U 0126 inhibits the reaction [S-Adenosylhomocysteine results in increased expression of MMP2 protein] |
CTD |
PMID:19770485 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
EXP |
S-Adenosylhomocysteine results in decreased expression of NFKBIA protein |
CTD |
PMID:19770485 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases abundance |
ISO |
NR0B2 protein results in decreased abundance of S-Adenosylhomocysteine |
CTD |
PMID:29416063 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions decreases methylation decreases expression |
ISO |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]; S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter] S-Adenosylhomocysteine results in decreased expression of OGG1 mRNA; S-Adenosylhomocysteine results in decreased expression of OGG1 protein |
CTD |
PMID:22064374 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
multiple interactions |
ISO |
PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine] |
CTD |
PMID:29416063 |
|
NCBI chr10:46,339,821...46,404,640
Ensembl chr10:46,339,821...46,404,642
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
S-Adenosylhomocysteine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions decreases methylation increases expression |
ISO |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] S-Adenosylhomocysteine results in increased expression of PSEN1 protein |
CTD |
PMID:19635394 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
affects abundance |
ISO |
SLC19A1 protein affects the abundance of S-Adenosylhomocysteine |
CTD |
PMID:15705887 |
|
NCBI chr20:12,334,675...12,354,517
Ensembl chr20:12,334,676...12,352,377
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
EXP |
S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter] |
CTD |
PMID:19770485 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression |
ISO |
S-Adenosylhomocysteine results in decreased expression of TIMP2 protein |
CTD |
PMID:19770485 |
|
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
|
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
S-methylthiocitrulline inhibits the reaction [EDN1 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:16380457 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions decreases activity |
EXP ISO |
[S-methylthiocitrulline results in decreased activity of NOS1 protein] which affects the abundance of Sodium [S-methylthiocitrulline results in decreased activity of NOS1 protein] which affects the susceptibility to Methamphetamine |
CTD |
PMID:11006970 PMID:12511180 |
|
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
S-methylthiocitrulline inhibits the reaction [Methamphetamine results in decreased activity of SLC18A2 protein]; S-methylthiocitrulline inhibits the reaction [Methamphetamine results in decreased expression of SLC18A2 protein] |
CTD |
PMID:17683483 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
AIFM1 protein inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased reduction of Glutathione]; AIFM1 protein promotes the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased reduction of Adenine Nucleotides] |
CTD |
PMID:15316071 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]; wortmannin promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]] |
CTD |
PMID:21138475 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of AQP3 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases phosphorylation multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of BAD protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of BAD protein] |
CTD |
PMID:21138475 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine results in increased expression of BAX protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased expression of BAX protein] |
CTD |
PMID:21138475 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein] S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 mRNA; S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein |
CTD |
PMID:17135264 PMID:21138475 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases secretion |
EXP |
Carbon Dioxide inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased secretion of CALCA protein] |
CTD |
PMID:18052948 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased activity of and results in increased cleavage of CASP1 protein |
CTD |
PMID:10903723 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity decreases activity |
ISO EXP |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of CASP3 protein] S-Nitroso-N-Acetylpenicillamine results in increased activity of CASP3 protein S-Nitroso-N-Acetylpenicillamine results in decreased activity of CASP3 protein Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased activity of CASP3 protein] |
CTD |
PMID:10811113 PMID:12006578 PMID:12220328 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine inhibits the reaction [3,5-dimethoxy-4'-hydroxystilbene results in decreased phosphorylation of CREB1 protein]; S-Nitroso-N-Acetylpenicillamine inhibits the reaction [Quercetin results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:17135264 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of CSRP3 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:104,147,205...104,166,389
Ensembl chr 1:104,147,206...104,166,367
|
|
G |
Drgx |
dorsal root ganglia homeobox |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of PRRXL1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr16:8,823,872...8,853,430
Ensembl chr16:8,823,872...8,853,430
|
|
G |
Edn1 |
endothelin 1 |
increases secretion |
EXP |
S-Nitroso-N-Acetylpenicillamine results in increased secretion of EDN1 protein |
CTD |
PMID:15640287 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eln |
elastin |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of ELN mRNA |
CTD |
PMID:12102619 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Exoc6 |
exocyst complex component 6 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of SEC15 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:256,211,879...256,369,318
Ensembl chr 1:256,226,179...256,368,813
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter] |
CTD |
PMID:10811113 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of FCGR3 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fcgr2b |
Fc fragment of IgG receptor IIb |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of FCGR2B mRNA |
CTD |
PMID:12102619 |
|
NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein] |
CTD |
PMID:16351512 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Ghrh |
growth hormone releasing hormone |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of GHRH mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:153,449,124...153,468,794
Ensembl chr 3:153,449,125...153,468,794
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions decreases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein] |
CTD |
PMID:16962941 PMID:19252090 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions decreases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] |
CTD |
PMID:16962941 PMID:19252090 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of GOT1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein]]; GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein]]; GPX1 protein affects the susceptibility to [Diquat co-treated with S-Nitroso-N-Acetylpenicillamine]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased expression of GPX1 protein] |
CTD |
PMID:11672444 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[S-Nitroso-N-Acetylpenicillamine co-treated with 2-tert-butylhydroquinone] results in increased expression of GSTA2 |
CTD |
PMID:15357004 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of HCK mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:148,579,917...148,623,026
Ensembl chr 3:148,579,920...148,623,033
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in increased expression of HMOX1 protein |
CTD |
PMID:16439612 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine inhibits the reaction [Streptozocin results in increased expression of IFNG protein] |
CTD |
PMID:15892581 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Itpka |
inositol-trisphosphate 3-kinase A |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of ITPKA mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 3:111,545,007...111,553,605
Ensembl chr 3:111,545,007...111,553,604
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases expression multiple interactions increases phosphorylation decreases phosphorylation |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:15640287 PMID:19252090 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases expression decreases phosphorylation increases phosphorylation multiple interactions |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of MAPK3 protein S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:15640287 PMID:19252090 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of MME mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:153,799,203...153,880,910
Ensembl chr 2:153,803,349...153,880,738
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
affects localization |
ISO |
S-Nitroso-N-Acetylpenicillamine affects the localization of MTF1 protein |
CTD |
PMID:16423564 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of NFKB1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases activity decreases expression |
ISO EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased activity of NOS2 protein S-Nitroso-N-Acetylpenicillamine results in decreased expression of NOS2 promoter |
CTD |
PMID:11076874 PMID:15565661 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
[S-Nitroso-N-Acetylpenicillamine co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11799084 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of NPR3 protein] |
CTD |
PMID:16962941 PMID:19252090 |
|
NCBI chr 2:61,883,946...61,950,291
Ensembl chr 2:61,888,950...61,949,926
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCA protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RAF1 protein]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RGS17 protein] |
CTD |
PMID:18652891 PMID:21235400 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Pam |
peptidylglycine alpha-amidating monooxygenase |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of PAM mRNA |
CTD |
PMID:12102619 |
|
NCBI chr 9:111,028,543...111,177,588
Ensembl chr 9:111,028,575...111,177,602
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] |
CTD |
PMID:10811113 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCA protein] |
CTD |
PMID:18652891 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions |
ISO |
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to PRKCG protein] |
CTD |
PMID:18652891 PMID:21235400 |
|
NCBI chr 1:64,407,098...64,433,698
Ensembl chr 1:64,407,114...64,433,636
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions increases activity |
EXP |
[S-Nitroso-N-Acetylpenicillamine co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] S-Nitroso-N-Acetylpenicillamine results in increased activity of PRKG1 protein |
CTD |
PMID:11799084 |
|
NCBI chr 1:248,982,039...250,300,952
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of RACK1 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr10:34,149,717...34,155,198
Ensembl chr10:34,149,717...34,155,198 Ensembl chr12:34,149,717...34,155,198
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RAF1 protein] |
CTD |
PMID:21235400 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rgs17 |
regulator of G-protein signaling 17 |
multiple interactions |
ISO |
S-Nitroso-N-Acetylpenicillamine promotes the reaction [OPRM1 protein binds to RGS17 protein] |
CTD |
PMID:18652891 |
|
NCBI chr 1:42,491,566...42,587,735
Ensembl chr 1:42,492,761...42,587,721
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
decreases expression |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of RPLP0 mRNA |
CTD |
PMID:12102619 |
|
NCBI chr12:46,791,528...46,794,797
Ensembl chr12:46,791,528...46,794,797
|
|
G |
Sftpa1 |
surfactant protein A1 |
decreases expression multiple interactions |
EXP |
S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr16:18,716,019...18,719,404
Ensembl chr16:18,716,019...18,719,403
|
|
G |
Sftpb |
surfactant protein B |
multiple interactions decreases expression |
EXP |
bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPB mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPB mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr 4:100,166,855...100,175,941
Ensembl chr 4:100,166,863...100,175,938
|
|
G |
Sftpc |
surfactant protein C |
multiple interactions decreases expression |
EXP |
bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPC mRNA]; PD 156707 inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPC mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr15:52,211,538...52,214,480
Ensembl chr15:52,211,544...52,214,616
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions affects response to substance |
ISO |
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in decreased activity of SOD1 protein] SOD1 protein affects the susceptibility to S-Nitroso-N-Acetylpenicillamine |
CTD |
PMID:10698074 PMID:11672444 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
GPX1 protein affects the reaction [S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein]]; S-Nitroso-N-Acetylpenicillamine promotes the reaction [Diquat results in increased activity of SOD2 protein] [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA |
CTD |
PMID:11672444 PMID:14996425 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of TRP53 mRNA S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein] |
CTD |
PMID:7673702 PMID:16351512 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
S-Nitroso-N-Acetylpenicillamine inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein] |
CTD |
PMID:20177073 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation |
EXP |
S-Nitroso-N-Acetylpenicillamine results in increased phosphorylation of VASP protein |
CTD |
PMID:11799084 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression increases secretion |
EXP |
S-Nitroso-N-Acetylpenicillamine results in increased expression of VEGFA mRNA S-Nitroso-N-Acetylpenicillamine results in increased secretion of VEGFA protein |
CTD |
PMID:10613739 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|